Lobaplatin

ApprovedSmall molecule

SSun Yat-sen University

Lobaplatin is one of 238 small molecule programs targeting Esophageal Carcinoma. It is currently in Approved.

Indications

Total Trials

Active Trials

237

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CarcinomaActive, not recruiting

OsteosarcomaActive, not recruiting

Triple-Negative Breast CancerApproved

Liver CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaApproved

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Triple-Negative Breast CancerApproved

Approved

Liver CancerPhase 3

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lobaplatin

SSun Yat-sen University

Approved

2 2

Avastin

Blenoxane

1 4

Voltaren

Novartis

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 9

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 10

Ablavar

LLantheus Medical Imaging

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Colorectal Cancer

NCT04845490

Q4 2029

Phase 3Not yet recruiting

Recurrent or Metastatic NPC

NCT05780294

Q3 2030

Post-ApprovalNot yet recruiting

Breast Cancer

NCT07093931

Clinical

Trials by Indication[1]

Clinical Trial2 trials

A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.

Unknown status·SSun Yat-sen University·Phase 2·NCT03210389·60 enrolled

Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial

Completed·FFifth Affiliated Hospital, Sun Yat-Sen University·Phase 1·NCT03188497·17 enrolled

Liver Cancer2 trials

Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05766605·90 enrolled

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Unknown status·ZZhujiang Hospital·Phase 3·NCT05701436·144 enrolled

Breast Cancer2 trials

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Not yet recruiting·SShandong Cancer Hospital and Institute·Phase 4·NCT07093931·468 enrolled

Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer

Unknown status·HHarbin Medical University·Phase 2·NCT01483300·80 enrolled

Triple-Negative Breast Cancer1 trial

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT05546255·40 enrolled

Concurrent Chemoradiotherapy1 trial

Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN

Unknown status·GGuiyang Medical University·Phase 2·NCT03117257·144 enrolled

7 more indications

Recurrent or Metastatic NPC1 trial

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT05780294·132 enrolled

Esophageal Carcinoma1 trial

Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma

Completed·HHenan Cancer Hospital·Phase 4·NCT03413436·733 enrolled

Osteosarcoma1 trial

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Recruiting·PPeking University People's Hospital·Phase 2·NCT06714383·50 enrolled

Gastric Cancer1 trial

Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04808466·231 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Unknown status·—·Phase 2·NCT06170697·46 enrolled

Colorectal Cancer1 trial

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT04845490·201 enrolled

Maintenance Therapy1 trial

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT03700359·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Lobaplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lobaplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lobaplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSun Yat-sen University

Lobaplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2029

Q3 2030

Trials by Indication[1]

Clinical Trial2 trials

Liver Cancer2 trials

Breast Cancer2 trials

Triple-Negative Breast Cancer1 trial

Concurrent Chemoradiotherapy1 trial

Recurrent or Metastatic NPC1 trial

Esophageal Carcinoma1 trial

Osteosarcoma1 trial

Gastric Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Colorectal Cancer1 trial

Maintenance Therapy1 trial

References

Drug Info

Quick Facts

Related News